Alpharma — Merger or Acquisition (September 2007)
18 slides from Alpharma's merger presentation, Sep 6, 2007
Slide 1: Ketoprofen in Transfersome Gel Licensing Agreement with IDEA Conference Call
Ketoprofen in Transfersome(r) Gel Licensing Agreement with IDEA Conference Call September 6, 2007
Slide 2: Forward Looking Statements
Forward Looking Statements Statements made in this presentation include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that cou
Slide 3: Agenda
Agenda The Ketoprofen in Transfersome(r) Gel Opportunity Dean Mitchell President & CEO Terms & Timeline Jeff Campbell Chief Financial Officer Closing Comments Dean Mitchell President & CEO Question and Answer Session
Slide 4: Expansion of Specialty Pharma Pipeline With Novel Technology
Ketoprofen in Transfersome(r) Gel: Expansion of Specialty Pharma Pipeline With Novel Technology Innovative and differentiated product Topical NSAID to treat chronic pain Novel Transfersome(r) technology Minimal systemic exposure Synergistic fit with ALO product portfolio Leverages pain management ex
Slide 5: The Topical NSAID Opportunity
The Topical NSAID Opportunity The NSAID/Cox-2 market exceeds $6 billion Significant concern regarding GI and CV safety Ketoprofen in Transfersome(r) Gel profile Potential to be first topical NSAID gel in the U.S. For the topical treatment of osteoarthritis Clinical effectiveness with minimal systemi
Slide 6: U.S. Prescriptions For NSAID Pain Relief Continue To Grow
U.S. Prescriptions For NSAID Pain Relief Continue To Grow 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr East 20.4 27.4 90 20.4 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 TRx (millions) 2003 2004 2005 2006 2007* NSAIDs 54.5 55.5 64.6 70.7 72 COX-2 50.1 50.8 33.4 12.8 12.7 Total Prescriptions (millions) Sourc
Slide 7: Osteoarthritis: The Medical Need
Osteoarthritis: The Medical Need Approximately 33 million U.S. adults suffer from OA By age 70, virtually all Americans are experiencing some form of arthritis NSAIDS are the most commonly used products to treat the pain and inflammation of OA NSAID's Higher Risk in Elderly Population
Slide 8: Alpharma's Market Research Indicates Positive Physician Response
Alpharma's Market Research Indicates Positive Physician Response to Ketoprofen in Transfersome(r) Gel Well tolerated, could compare favorably to oral NSAIDs Minimal systemic absorption Fewer concerns about GI, renal and/or cardiovascular effects Effective analgesia 6 week comparative study with Cele
Slide 9: Physicians Surveyed Saw Clear Market Position for Gel
Physicians Surveyed Saw Clear Market Position for Ketoprofen in Transfersome(r) Gel Gel will be used for variety of chronic pain situations Physicians will use for osteoarthritis (especially of the knee), but also for other joints (e.g. shoulder or elbow) Physicians would use for other chronic pain
Slide 10: European Clinical Results
European Clinical Results In May 2007, IDEA AG submitted a marketing authorization in Europe for ketoprofen in Transfersome(r) gel for the short and long-term treatment of osteoarthritis EMEA submission includes results from four Phase II and III clinical studies in over 2000 patients with osteoarth
Slide 11: Ketoprofen in Transfersome Clinical Development Plan
Ketoprofen in Transfersome(r) Clinical Development Plan TRIAL 1 12-week 3-arm trial, 50 and 100 mg vs. placebo gel TRIAL 2 12-week 5-arm trial, 50 and 100 mg vs. placebo gel, and Celebrex vs. oral placebo Non-inferiority analyses for Celebrex arms Targeting an NDA submission in late 2009 U.S. produc
Slide 12: Potential Synergies
Potential Synergies Ketoprofen in Transfersome(r) gel and Flector(r) Patch would be complementary and address a broad range of patient types and needs Different indications Gel and patch formulations Commercialization Sales force synergies with overlapping physician target audience Medical education
Slide 13: Key Terms of the Agreement
Key Terms of the Agreement $60 million payment at closing Milestone payments 3 progress payments based upon the achievement of clinical and regulatory milestones; $77 million 1 payment of $45 or $65 million based on regulatory approval IDEA to fund agreed clinical studies through approval Commitment
Slide 14: Stock Warrants
Stock Warrants Two series (A: Phase III success and B: FDA approval) Both series vest only upon FDA approval Strike price per share: Series A: 50% premium of the 30 day average stock price preceding announcement of positive Phase III results, with a floor of $22.50 Series B: 25% premium of the 30 da
Slide 15: Financial Implications and Expected Timeline
Financial Implications and Expected Timeline 2007 $60 million payment upon closing $5 million ($0.10 EPS) transaction-related costs Potential milestone payments 2008 - 2009 Modest market development and infrastructure expenses Potential milestone payments 2010 Pre-launch market preparation Product a
Slide 16: Strong Pharmaceutical Product Pipeline
Strong Pharmaceutical Product Pipeline Phase 1 Phase 2 Phase 3 Approved KADIAN(r) Flector(r) Patch Tirosint(r) ALO-01(KADIAN(r) NT) ALO-02(Oxycodone NT) ALO-03(Tris) Ketoprofen in Transfersome(r) Gel Building a Balanced, Diversified Portfolio to Deliver Sustainable Growth
Slide 17: Summary
Ketoprofen in Transfersome(r) Gel Summary Compelling market opportunity and product profile Highly complementary with Flector(r) Patch Establishes Alpharma as leader in topical NSAID market Investment supports multiple major product launches over next several years Focus on Execution
Slide 18: Questions & Answers
QUESTIONS & ANSWERS 7